The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).

Evan Y.  Yu

Consulting or Advisory Role - Agensys; AstraZeneca; Bayer; Dendreon; EMD Serono; Ferring; Genentech/Roche; Janssen; Lilly; Medivation; Merck; Tokai Pharmaceuticals

Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); GTx (Inst); Lilly/ImClone (Inst); Merck (Inst)

Haiyan  Wu

Employment - Bayer; Merck

Stock and Other Ownership Interests  - Bayer; Merck; Novartis; Novo Nordisk

Charles  Schloss

Employment - Merck

Stock and Other Ownership Interests  - Merck